• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C.
【24h】

Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C.

机译：在慢性丙型肝炎中，宿主药效学作用与对聚乙二醇化干扰素α-2a/利巴韦林的病毒学应答相关。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients receiving therapy for chronic hepatitis C virus (HCV) infection frequently experience cytopenias and weight loss. We retrospectively assessed the pharmacodynamic effects of pegylated interferon (PEG-IFN) alfa-2a and ribavirin by evaluating the relationship between changes in hematologic parameters, body weight, and virologic response. Patients with HCV genotypes 1, 4, 5, or 6 receiving 24 or 48 weeks of PEG-IFN alfa-2a and ribavirin therapy were pooled from four phase 3/4 trials. Maximum decreases in hemoglobin level, neutrophil count, platelet count, and weight during therapy were assessed according to virologic response category (sustained virologic response [SVR], relapse, breakthrough, and nonresponder) and race/ethnicity. Of 1,778 patients analyzed, more than half were male, non-Hispanic Caucasian, and infected with HCV genotype 1; had a baseline HCV RNA >800,000; and had alanine aminotransferase levels
机译：接受慢性丙型肝炎病毒（HCV）感染治疗的患者经常会出现血细胞减少和体重减轻。我们通过评估血液学参数，体重和病毒学应答之间的关系，回顾性评估了聚乙二醇化干扰素（PEG-IFN）alfa-2a和利巴韦林的药效学作用。 HCV基因型1、4、5或6的患者接受了24或48周的PEG-IFN alfa-2a和利巴韦林疗法的治疗，来自4个3/4期试验。根据病毒学应答类别（持续病毒学应答[SVR]，复发，突破和无应答）和种族/种族，评估治疗期间血红蛋白水平，中性粒细胞计数，血小板计数和体重的最大下降。在分析的1,778例患者中，一半以上是男性，非西班牙裔白种人，并感染了HCV基因型1。基线HCV RNA> 800,000;且丙氨酸氨基转移酶水平

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号